近日，来自斯坦福大学医学院Matthew P. Scott教授领导的研究团队在国际学术期刊elife上发表了一项最新研究进展，他们利用小鼠模型检测了一种叫做Roflumilast的药物对一种常见的儿童脑部肿瘤--成神经管细胞瘤的治疗作用，Roflumilast...近日，来自斯坦福大学医学院Matthew P. Scott教授领导的研究团队在国际学术期刊elife上发表了一项最新研究进展，他们利用小鼠模型检测了一种叫做Roflumilast的药物对一种常见的儿童脑部肿瘤--成神经管细胞瘤的治疗作用，Roflumilast目前主要用于炎症性肺部疾病的治疗。
在这项研究中，研究人员发现了调控Hedgehog信号应答的一个新的重要方式。他们发现一个叫做Semaphorin3的蛋白能够增强细胞对Hedgehog信号的应答，并且在成神经管细胞瘤中Semaphorin3表达水平出现显著增加，因此研究人员对阻断Sema-phorin3的作用能否抑制细胞对Hedgehog信号的应答进而抑制细胞分裂进行了研究。展开更多
Phosphodiesterase-4(PDE4)has been demonstrated to be a promising target for treatment of Alzheimer’s disease(AD).Roflumilast(Rof),a potent PDE4 inhibitor,has been approved for treatment of chronic obstructive pulmona...Phosphodiesterase-4(PDE4)has been demonstrated to be a promising target for treatment of Alzheimer’s disease(AD).Roflumilast(Rof),a potent PDE4 inhibitor,has been approved for treatment of chronic obstructive pulmonary disease(COPD)in humans.Recent studies have shown that Rof improves cognition at doses that do not cause an emetic response,the major side-effect of PDE4 inhibitors.However,the effect of Rof on cognition associated with AD remains largely unknown.Here we examined the effects of Rof on behavioral dysfunction and the related mechanisms in APP/PS1 double transgenic mice,a widely used model for AD.Mice at 10 months of age were first tested in novel object recognition for memory.The recognition index in APP/PS1 mice was decreased compared to WT mice,which was reversed by Rof at 5 and 10 mg·kg-1.This was then verified in the Morris water-maze test.The escape latency during acquisition training was significantly longer and the entries into the target quadrant during the probe trial were much less compared to WT controls,these were also reversed by Rof.In the tail-suspension and forced-swimming tests,which measure depression-like behavior,APP/PS1 mice showed prolonged immobility time,which was reversed by Rof.In addition,the staining of HE and Nissl showed that Rof reduced the loss of neurons and neurocyte apoptosis in APP/PS1 mice.It also reversed the decreased ratio of Bcl-2/BAX and inhibited the increased expression of PDE4D in the cerebral cortex and hippocampus of APP/PS1 mice.Finally,Rof reversed the decreased levels of cAMP and expression of phosphorylated cAMP response element-binding protein(CREB)and brain derived neurotrophic factor(BDNF)in APP/PS1 mice.Overall,these results suggest that Rof not only improves learning and memory,but attenuates depression-like behavior in AD mice,likely via PDE4D/cAMP/CREB/BDNF signaling-mediated neuroprotection.Therefore,Rof can be a therapeutic agent for AD,in particular the comorbidity of memory deficits and depression.展开更多
文摘近日，来自斯坦福大学医学院Matthew P. Scott教授领导的研究团队在国际学术期刊elife上发表了一项最新研究进展，他们利用小鼠模型检测了一种叫做Roflumilast的药物对一种常见的儿童脑部肿瘤--成神经管细胞瘤的治疗作用，Roflumilast目前主要用于炎症性肺部疾病的治疗。
在这项研究中，研究人员发现了调控Hedgehog信号应答的一个新的重要方式。他们发现一个叫做Semaphorin3的蛋白能够增强细胞对Hedgehog信号的应答，并且在成神经管细胞瘤中Semaphorin3表达水平出现显著增加，因此研究人员对阻断Sema-phorin3的作用能否抑制细胞对Hedgehog信号的应答进而抑制细胞分裂进行了研究。
基金This work was supported by research grants from National Natural Science Foundation of China(81773717 to HTZ81601229 and 81441111 to HW).
文摘Phosphodiesterase-4(PDE4)has been demonstrated to be a promising target for treatment of Alzheimer’s disease(AD).Roflumilast(Rof),a potent PDE4 inhibitor,has been approved for treatment of chronic obstructive pulmonary disease(COPD)in humans.Recent studies have shown that Rof improves cognition at doses that do not cause an emetic response,the major side-effect of PDE4 inhibitors.However,the effect of Rof on cognition associated with AD remains largely unknown.Here we examined the effects of Rof on behavioral dysfunction and the related mechanisms in APP/PS1 double transgenic mice,a widely used model for AD.Mice at 10 months of age were first tested in novel object recognition for memory.The recognition index in APP/PS1 mice was decreased compared to WT mice,which was reversed by Rof at 5 and 10 mg·kg-1.This was then verified in the Morris water-maze test.The escape latency during acquisition training was significantly longer and the entries into the target quadrant during the probe trial were much less compared to WT controls,these were also reversed by Rof.In the tail-suspension and forced-swimming tests,which measure depression-like behavior,APP/PS1 mice showed prolonged immobility time,which was reversed by Rof.In addition,the staining of HE and Nissl showed that Rof reduced the loss of neurons and neurocyte apoptosis in APP/PS1 mice.It also reversed the decreased ratio of Bcl-2/BAX and inhibited the increased expression of PDE4D in the cerebral cortex and hippocampus of APP/PS1 mice.Finally,Rof reversed the decreased levels of cAMP and expression of phosphorylated cAMP response element-binding protein(CREB)and brain derived neurotrophic factor(BDNF)in APP/PS1 mice.Overall,these results suggest that Rof not only improves learning and memory,but attenuates depression-like behavior in AD mice,likely via PDE4D/cAMP/CREB/BDNF signaling-mediated neuroprotection.Therefore,Rof can be a therapeutic agent for AD,in particular the comorbidity of memory deficits and depression.
